A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Atazanavir (Atazanavir Sulfate)

Protease Inhibitor class · 4 generic manufacturers · 14 ANDAs filed at FDA.

First FDA approval2003-06-24
Generic availableYes · 4 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$6.8M in CY2024 Part D spend16K claims · 3K beneficiaries · 329 plans surveyed

Lowest NADAC
$1.09/unit
10 NDCs benchmarked, lowest of all strengths.
Average NADAC
$1.89
Across all dosage forms in distribution.
Highest NADAC
$2.70
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Atazanavir used for?

Atazanavir is a Protease Inhibitor medication tracked in Medicare Part D.

Is there a generic for Atazanavir?

Yes. 14 ANDAs filed at FDA, 4 generic manufacturers currently shipping.

How much does my plan pay for Atazanavir?

Across 329 Part D plans, Atazanavir averages $1.89/unit (NADAC). Lowest available: $1.09/unit. Highest in distribution: $2.70/unit.

Is Atazanavir on the FDA shortage list?

Atazanavir has been discontinued by its manufacturer(s).

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Protease Inhibitor2 alternatives in D1
01
Darunavir
Brand: PREZISTA
$1.13Lowest NADAC
10Generic mfrs
$81.7MCY24 Part D spend
Compare →
02
Tipranavir
Brand: Aptivus
Lowest NADAC
0Generic mfrs
$1.5MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (10 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.